According to NICE guidance (NG28) , GLP-1 receptor agonists like Rybelsus may be considered when triple therapy is not effective, tolerated or contraindicated, particularly for patients with a BMI 35 kg/m (or lower in certain ethnic groups) or those with significant weight or cardiovascular concerns
Although rare, pancreatitis is a recognised serious adverse effect of GLP-1 receptor agonists
Then, in 2023, the US FDA approved tirzepatide 5 mg, 10 mg and 15 mg for chronic weight management
Chemical degradation pathways Beyond denaturation, heat exposure promotes at least two other degradation pathways
While its effects on weight loss are well-documented, many people have questions about its potential impact on other areas of healthespecially dental health
doi: 10.1017/S0007114513002286 69 RakaFFarrSKellyJStoianovAAdeliK